Table 1. Clinical characteristics in all 101 patients.
| Features | TKI with intracavitary therapy (n=43), n (%) | TKI alone (n=58), n (%) | P value |
|---|---|---|---|
| Sex | 0.867 | ||
| Male | 20 (46.5) | 26 (44.8) | |
| Female | 23 (53.5) | 32 (55.2) | |
| Age | 0.652 | ||
| <65 years | 30 (69.8) | 38 (65.5) | |
| ≥65years | 13 (30.2) | 20 (34.5) | |
| Smoking | 0.787 | ||
| Yes | 13 (30.2) | 19 (32.8) | |
| No | 30 (69.8) | 39 (67.2) | |
| Types of TKI | 0.692 | ||
| Erlotinib | 2 (4.7) | 1 (1.7) | |
| Gefitinib | 7 (16.3) | 10 (17.2) | |
| Icotinib | 34 (79.1) | 47 (81.0) | |
| PS at EGFR-TKIs treatments | 0.118 | ||
| 0–1 | 29 (67.4) | 47 (81.0) | |
| 2 | 14 (32.6) | 11 (19.0) | |
| Types of EGFR mutation | 0.471 | ||
| 19 | 25 (58.1) | 30 (51.7) | |
| 21L858R | 14 (32.6) | 25 (43.1) | |
| Others | 4 (9.3) | 3 (5.2) | |
| Lines of EGFR-TKI | 0.078 | ||
| First line | 31 (72.1) | 50 (86.2) | |
| Second line or more | 12 (27.9) | 8 (13.8) |
PS, performance status; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.